FDA

The era of personalized medicine is fast approaching and, in many therapeutic areas such as oncology, is already underway.

A regulatory perspective on the current state of protein science and the implications for biosimilar approval.

Current clinical trials are regarded as “too slow, too expensive, not reliable, and not designed to answer the important questions,” according to FDA’s new deputy commissioner for medical products &tobacco, Robert Califf.

Among the multiple proposals for stimulating drug development and revising regulatory processes, the 21st Century Cures initiative includes several provisions designed to streamline clinical research and the amount of data required to gain FDA approval of certain indications.

Demands from patient advocacy groups for broader subgroup representation in clinical trials has generated a new drug trial transparency initiative at the Center for Drug Evaluation and Research (CDER).

Media rebuke of Europe’s Innovative Medicines Initiative thrusts debate into the public arena.

The productivity of the U.S. biomedical research enterprise is undergoing a broad re-examination.

FDA commissioner Margaret Hamburg has received praise and plaudits as she exits the Food and Drug Administration this week after six years on the job.

Vice President of Global Regulatory Affairs, Theorem Clinical ResearchIntroduction

While such discussions have advanced in Europe, two key omissions from the dialogue may limit any real changes.

The main surprise at the Jan. 7, 2015 meeting of FDA’s Oncologic Drugs Advisory Committee was the panel’s strong support for a drug developed under a very different model from most cancer therapies.

FDA set several milestones in approving more new, important drugs and biologics in 2014.

In a health policy world where competition for profile is tough, a vacuum at the top is a serious disadvantage.

The technology necessary to meet the expected regulatory demands for assessing drug-impaired driving has emerged.

Reshuffling to heavily impact life sciences policy in Europe.

There are 7,000 rare diseases affecting approximately 350 million people around the world.

With the passage of the Biosimilar Price Competition and Innovation Act in 2009, the U.S. created new pathways for development and approval of biosimilar and interchangeable products.

Pharmacovigilance is the next frontier for outsourcing in the pharmaceutical and biologics industry.

Claims of success for pharmacovigilance are under question, but hopes are higher for new clinical trials rules.

One of the many activities across the clinical development cycle that is non-negotiable is the creation, collection, management, and storage of the documents that are contained in the Trial Master File.

The advent of new drugs for tuberculosis is posing some interesting challenges for regulators in Europe.

Pharmaceutical companies are jumping on the clinical trial transparency bandwagon, while also seeking to protect confidential information.